Novo Nordisk, a global healthcare company, and Valo Health, which specializes in AI-driven drug development to streamline the creation of new medicines, are working together more to find and create new medicines to treat obesity, type 2 diabetes, and heart disease. Originally partnering in September 2023, the agreement now covers up to 20 drug programs, with the potential to generate up to $4.6 billion in milestone payments, plus R&D funding and royalties. Valo, leveraging its Opal Computational Platform, will continue using human data and AI to accelerate drug discovery. This expansion follows early successes in identifying new drug targets and preclinical drug discovery programs.
Under the terms of the updated agreement, Valo will receive a $190 million upfront payment, equity investment, and potential milestone payments. Novo Nordisk will work with Valo to further analyze patient data and genetic information, deepening their research into cardiometabolic diseases. Both companies are focused on using AI and real-world patient data to validate therapeutic targets and enhance the development of small molecule therapies for these conditions.
